Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Merck’s vaccines division earned $12.85bn revenues in 2024, or ~22% of all revenues, with HPV vaccine Gardasil driving >$8.5bn of revenues, and measles vaccine ProQuad earning ~$2.5bn.

Shares fell more than 10% as Merck paused Gardasil shipments to China, and 2025 sales guidance of $64.1 billion-$65.6 billion implies flat to 2% growth. Merck's Keytruda Dominance and a Strong ...

Merck does have other products that can also generate billions in revenue in the future. Gardasil, its vaccine for the human papillomavirus (HPV), may generate $11 billion in revenue by 2030 ...